Does SITAGLIPTIN Cause Hepatocellular carcinoma? 18 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 18 reports of Hepatocellular carcinoma have been filed in association with SITAGLIPTIN (JANUVIA). This represents 0.1% of all adverse event reports for SITAGLIPTIN.
18
Reports of Hepatocellular carcinoma with SITAGLIPTIN
0.1%
of all SITAGLIPTIN reports
5
Deaths
6
Hospitalizations
How Dangerous Is Hepatocellular carcinoma From SITAGLIPTIN?
Of the 18 reports, 5 (27.8%) resulted in death, 6 (33.3%) required hospitalization, and 3 (16.7%) were considered life-threatening.
Is Hepatocellular carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for SITAGLIPTIN. However, 18 reports have been filed with the FAERS database.
What Other Side Effects Does SITAGLIPTIN Cause?
Blood glucose increased (1,427)
Pancreatic carcinoma (1,142)
Product dose omission issue (1,125)
Drug ineffective (1,057)
No adverse event (994)
Nausea (936)
Pancreatitis (922)
Diabetes mellitus inadequate control (744)
Diarrhoea (712)
Hypoglycaemia (674)
What Other Drugs Cause Hepatocellular carcinoma?
SORAFENIB (1,665)
RIBAVIRIN (1,046)
SOFOSBUVIR (877)
LEDIPASVIR\SOFOSBUVIR (640)
BEVACIZUMAB (532)
REGORAFENIB (470)
DACLATASVIR (419)
ATEZOLIZUMAB (342)
CABOZANTINIB S-MALATE (219)
TACROLIMUS (183)
Which SITAGLIPTIN Alternatives Have Lower Hepatocellular carcinoma Risk?
SITAGLIPTIN vs SOAP
SITAGLIPTIN vs SODIUM
SITAGLIPTIN vs SODIUM BICARBONATE
SITAGLIPTIN vs SODIUM BICARBONATE\SODIUM
SITAGLIPTIN vs SODIUM BORATE